634 completed, 163 terminated, 124 recruiting, 104 unknown. 1187 Phase 2, 233 Phase 1, 84 Phase 3.
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital | Phase 1 / Phase 2 | Not yet recruiting | Agnieszka Czechowicz | 12 | 2028-01-01 | 2026-06-16 |
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 59 | 2027-08-01 | 2026-10-21 |
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| CK0801 for Treatment of Aplastic Anemia CK0801 - Aplastic Anemia | Phase 2 | Not yet recruiting | Cellenkos, Inc. | 12 | 2026-12-03 | 2026-10-20 |
| Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia. Spironolactone (drug), Iron Supplement, Erythropoietin stimulating agent - Anemia | Phase 2 | Not yet recruiting | Ain Shams University | 40 | 2026-12-01 | 2026-07-20 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy Allogeneic Stem Cell Transplant - MDS, Myelodysplastic Syndrome MDS | Phase 2 | Not yet recruiting | Ronald Paquette | 20 | 2026-12-01 | 2026-10-28 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-11-04 | 2026-10-30 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Feasibility and Acceptability of Amani Amani - Sickle Cell Disease | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2026-11-01 | 2026-08-07 |
| A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions Ofirnoflast - Myelodysplastic Syndromes, Anemia | Phase 2 | Not yet recruiting | Halia Therapeutics, Inc. | 70 | 2026-11-01 | 2026-10-02 |
| Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria SGB-9768 - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | Suzhou Sanegene Bio Inc. | 24 | 2026-10-31 | 2026-09-04 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 40 | 2026-10-01 | 2026-09-09 |
| Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 2 | Recruiting | Mohsen Saidinejad | 120 | 2026-09-10 | 2026-09-02 |
| Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes Dapagliflozin (10mg Tab) - Myelodysplastic Syndromes (MDS), Anemia | Phase 2 | Not yet recruiting | Seug yun Yoon, MD | 37 | 2026-09-01 | 2026-04-08 |
| Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia HGI-001 Injection - Beta Thalassemia Transfusion Dependent | Phase 2 | Not yet recruiting | Prince of Wales Hospital, Shatin, Hong Kong | 6 | 2026-09-01 | 2026-07-23 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-01 | 2026-07-23 |
| Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) BMS-986353, Fludarabine Phosphate, Cyclophosphamide - Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | Phase 2 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 52 | 2026-08-31 | 2026-07-09 |
Showing 20 of 1187. Sign in to see all of them.
Anemia, Sickle Cell (293) · Myelodysplastic Syndromes (191) · Anemia, Aplastic (183) · Anemia, Refractory, with Excess of Blasts (178) · Leukemia, Myeloid, Acute (128) · Leukemia (122) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (93) · Leukemia, Myelomonocytic, Chronic (88) · beta-Thalassemia (87) · Thalassemia (71) · Hemoglobinuria, Paroxysmal (70) · Myeloproliferative Disorders (68) · Anemia, Refractory (67) · Lymphoma, Non-Hodgkin (62)
Hemic and Lymphatic Diseases (1186) · Hematologic Diseases (1147) · Bone Marrow Diseases (506) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (505) · Anemia, Hemolytic (487) · Genetic Diseases, Inborn (437) · Anemia, Hemolytic, Congenital (390) · Hemoglobinopathies (358) · Pathological Conditions, Signs and Symptoms (334) · Pathologic Processes (300) · Disease Attributes (249) · Neoplasms (244) · Neoplasms by Histologic Type (237) · Chronic Disease (223)
Cyclophosphamide (126) · fludarabine phosphate (91) · Cyclosporine (82) · fludarabine (79) · Busulfan (75) · Antilymphocyte Serum (72) · Whole-Body Irradiation (72) · Mycophenolic Acid (63) · Epoetin Alfa (58) · Alemtuzumab (48) · Tacrolimus (48) · Hydroxyurea (44) · Filgrastim (43) · Peripheral Blood Stem Cell Transplantation (42) · Melphalan (41)
National Heart, Lung, and Blood Institute (NHLBI) (53) · Novartis Pharmaceuticals (33) · Fred Hutchinson Cancer Center (31) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (30) · Masonic Cancer Center, University of Minnesota (21) · Institute of Hematology & Blood Diseases Hospital, China (19) · Amgen (18) · Alexion Pharmaceuticals, Inc. (16) · M.D. Anderson Cancer Center (16) · National Cancer Institute (NCI) (16) · Memorial Sloan Kettering Cancer Center (15) · St. Jude Children's Research Hospital (15) · Assistance Publique - Hôpitaux de Paris (13) · Children's Hospital Medical Center, Cincinnati (12) · GlaxoSmithKline (12)
United States (673) · United Kingdom (109) · China (92) · Italy (91) · France (79) · Canada (73) · Germany (68) · South Korea (39) · Spain (38) · Lebanon (32) · Turkey (Türkiye) (31) · Australia (28) · Japan (25) · Egypt (24) · Thailand (24)
Neal S Young, M.D. (6) · Danielle M Townsley, M.D. (5)
PMID 36005278, PMID 36240296, PMID 33783815, PMID 34724566, PMID 37975597, PMID 36791280, PMID 42133908, PMID 23738544, PMID 29958797, PMID 34175041, PMID 37254256, PMID 29674506, PMID 32499241, PMID 38775255, PMID 40569673, PMID 20685256, PMID 22055111, PMID 22067384, PMID 25310303, PMID 25824692, PMID 26494831, PMID 29669226, PMID 29931453, PMID 30957581, PMID 30992268, PMID 32343796, PMID 32384147, PMID 33283989, PMID 34922648, PMID 34932836, PMID 35007144, PMID 36355805, PMID 36529836, PMID 36860093, PMID 36975201, PMID 38866240, PMID 40010689, PMID 40593138, PMID 41026975, PMID 41114449, PMID 41124654, PMID 41809202, PMID 41871072, PMID 41954645, PMID 42224366, PMID 42549972, PMID 42749863, PMID 10029607, PMID 1090310, PMID 10924610
P30CA015704 (14), 2014 (9), 2016 (9), 2017 (8), 2018 (8), 2023 (8), P01CA018029 (7), P30CA043703 (6), 2005 (5), 2015 (5), 2019 (5), P30CA006973 (5), 2008 (4), P30CA016672 (4), U01HL065238 (4)